RPL554 - Biotech, Pharma and Life Science Channel
Verona’s lead drug, RPL554, is a dual phosphodiesterase (PDE) 3 and 4 inhibitor being developed as a novel treatment for chronic obstructive airways disease as COPD (chronic obstructive pulmonary disease) and asthma with bronchodilator and anti-inflammatory effects. Both effects are essential to aid breathing, especially in sufferers of COPD. There is currently no drug combining both effects in a single molecule. In addition, current treatments have unwanted side effects and/or limited effectiveness. The product is currently in clinical trials for both diseases.
News Articles
Verona Pharma: Interim Results for the Six Months Ended 30 June2012
14 September 2012 - London, UK - Verona Pharma plc (AIM: VRP.L), is a drug development company with first-in-class drugs to treat respiratory diseases, such as chronic obstructive pulmonary disea...
Verona Pharma Reports Bronchodilator Data with RPL554 in COPD Patients at the 2012 ERS
4 September 2012 - London, UK - Verona Pharma plc (AIM: VRP.L), the drug discovery and development company with first-in-class drugs to treat respiratory diseases, today announces the completion...
New Data on RPL554 in COPD to be Presented at ERS Annual Congress
3 September 2012 - London, UK – Verona Pharma plc (AIM: VRP.L), the drug discovery and development company with first-in-class drugs to treat respiratory diseases, announces that new data o...
US Patent Granted for Verona Pharma's RPL554
28 August 2012 - London, UK - Verona Pharma plc (AIM: VRP.L), the drug discovery company with first-in-class drugs to treat respiratory diseases, today announces that the United States Patent and...
9 July 2012 - London, UK - London, UK - Verona Pharma plc (AIM: VRP.L), the biotechnology company focused on developing novel treatments for chronic respiratory diseases, today announces that it...
Verona Pharma - CEO's Statement to Annual General Meeting
1st June 2012: At the Annual General Meeting of Verona Pharma being held today, the Company's Chief Executive Officer, Professor Michael Walker, will make the following statement: “Ve...
1 May 2012 - London, UK - Verona Pharma plc (AIM: VRP.L), the Company focused on discovering and developing first-in-class drugs for respiratory disease, today announced the appointment of Dr Sve...
Verona Pharma Preliminary Unaudited Results for the twelve months ended 31 December 2011
April 5th 2012: Verona Pharma plc is a biotechnology company dedicated to discovering new drugs for the treatment of chronic respiratory diseases, such as chronic obstructive pulmonary disea...
Highlights: Premier UK clinical research facility, Medicines Evaluation Unit in Manchester, contracted to carry out Phase II anti-inflammatory trial Enrollment of patients to start Q2, w...
Verona Pharma successfully completes £3.25 million placing
Verona Pharma plc (“Verona Pharma” or the “Company”) 8 December 2011 - London, UK - Verona Pharma plc (AIM: VRP.L), the biotechnology company dedicated to discoveri...
Events
None
Companies
None
Clinical Trials
None
PubMed Articles
None
